Alkem Lab Q1 FY27 Earnings Call — Analysis (NSE: ALKEM)
India branded growth at 12% offsets Trade Generics flatness; Daman facility receives OAI but supply uninterrupted; U.S. CDMO drag persists at ₹60 Cr per quarter.
Result quality: watch — Margin pressure. Management sentiment: neutral.
The take
Q1FY27 Revenue from operations ₹3,740 Cr ( +11% YoY ) . New guidance — FY27 india revenue growth close to 12% .
Results
Revenue ₹3,740 Cr +11% YoY; EBITDA margin 20.5%; Net profit degrew 21.7% due to higher tax; India sales 10.3% (branded 12%, Trade Generics flat), international +16%.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue from operations | ₹3,740 Cr | +11% | yoy · Q1FY27 |
| India sales | ₹2,497 Cr | +10.3% | yoy · Q1FY27 |
| International sales | ₹1,222 Cr | +16% | yoy · Q1FY27 |
| EBITDA margin | 20.5% | +na | none · Q1FY27 |
| PBT growth (YoY) | 1.8% | +1.8% | yoy · Q1FY27 |
| Net profit growth (YoY) | -21.7% | -21.7% | yoy · Q1FY27 |
| R&D spend as % of revenue | 4% | +na | none · Q1FY27 |
Guidance
FY27 India revenue growth upgraded to ~12% (100bps above earlier guide); U.S. mid-to-high single digit; gross margin maintained at 66.5–67% for rest of year.
What management committed to
- India FY27 overall revenue growth could end up close to 12%. — close to 12%, FY27
- U.S. full-year revenue growth will be mid to high single digit in FY27. — mid to high single digit, FY27
- Gross margins will be in the range of 66.5% to 67% for the balance part of FY27. — 66.5% to 67%, FY27
- Consolidated tax rate for FY27 will be in the range of 30% to 32%. — 30% to 32%, FY27
- Occlutech will deliver around ₹400 Cr of sales with breakeven EBITDA in the 8.5 months of FY27 after acquisition. — around ₹400 Cr of sales with breakeven EBITDA, FY27
- Daman OAI will be resolved in 6 to 12 months and will have no impact on U.S. business this fiscal year. — 6–12 months, no FY27 impact, FY27
- U.S. CDMO break-even will be achieved when annualised revenue reaches $25–30 million, likely by FY28.
Key themes
Branded IPM outperformance, Trade Generics credit reset, Daman OAI resolution
Operational commentary
- India branded generics grew 12% YoY, outperforming IPM in 7 key therapies; anti-infectives 1.1x, gastro 1.2x, vitamins 1.4x, pain 1.8x, antidiabetic 1.4x, respiratory 1.6x, derma 1.6x. Trade Generics flat due to credit discipline and price increases, but six-month Jan-Jun growth high single digit.
- Daman facility received OAI status; corrective actions initiated, no supply interruption. 45% of U.S. revenue comes from this facility; management expects resolution in 6–12 months without business impact.
- U.S. CDMO (Enzene) quarterly opex ₹60 Cr, not yet breakeven. Breakeven requires ~$25–30M annualized revenue, likely by FY28. Facility not yet U.S. FDA-approved but working with clients for future triggers.
- Biosimilars: India launched 7 products, annual sales ₹150 Cr, margins improving due to backward integration. Prolia biosimilar EU launch through Theramex expected to be gradual; Xgeva launch in Europe in ~3 months.
- MedTech: Occlutech acquisition closed mid-July 2026; FY27 target ₹400 Cr sales with breakeven EBITDA over 8.5 months, gradual margin improvement targeting 7–8% EBITDA YoY gains, healthy margins in 3–4 years.
- International non-U.S. markets: Chile, Australia growing well; double-digit growth sustainable but small base, not yet moving the needle vs. U.S.
- CEO search ongoing, hopeful of appointment by next quarterly call.
- Gross margin improved in Q1 due to mix (lower Trade Generics) and currency; guidance 66.5–67% for rest of FY27 despite API price pressure.
Analyst Q&A
Q. Why India growth 10.3% lower than peers?
Trade Generics growth was flattish due to tightened credit terms and increased prices; branded generic growth was 12%.
Q. Breakeven timeline and revenue needed for U.S. CDMO?
Next 12 months will not break even; annualised revenue of $25–30M needed to break even, likely FY28.
Q. When will Trade Generics growth bounce back to branded levels?
Hard to match branded growth; happy with late single digits, focusing on discipline and ROCE.
Q. Outlook on Daman OAI and impact on U.S. business?
Confident no business impact this year; resolution expected in 6–12 months; supplies continue.
Research and educational content only. Not investment advice.